Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Xencor (XNCR) and GeneDx Holdings (WGS)
Piper Sandler Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $30
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study Of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody For Treatment Of Inflammatory Bowel Disease
Express News | Xencor Inc - Xmab942 Well Tolerated in Single and Multiple Doses
Express News | Xencor Inc - Lead Selection for Xmab Tl1a X Il23P19 Program on Track for First-in-Human Study Start in 2026
Express News | Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of Xmab942, a High-Potency Extended Half-Life Anti-Tl1a Antibody, in Development for Treatment of Inflammatory Bowel Disease
William Blair Initiates Xencor(XNCR.US) With Buy Rating
Xencor Analyst Ratings
William Blair Initiates Xencor at Outperform
Xencor Participates in a Conference Call With JPMorgan
Top Executive Sells Thousands of Xencor Shares!
Insider Sale: SR. VICE PRESIDENT & CFO of $XNCR Sells 3,750 Shares
Sector Update: Health Care
Sector Update: Health Care Stocks Gain in Afternoon Trading
AI-focused Drug Discovery Firms Rise as FDA Phases Out Animal Testing
US FDA Animal Testing De-Emphasis May Boost Biotech Innovation, RBC Says
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Express News | Xencor Appoints Todd Simpson to Board of Directors
Insider Sale: EVP of $XNCR Sells 2,565 Shares